ALX Oncology Holdings Inc expected to post a loss of 87 cents a share - Earnings Preview

ALX Oncology Holdings

03/11/2023 12:53

* ALX Oncology Holdings Inc  ALXO.OQ   ALXO.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for ALX Oncology
Holdings Inc
is for a loss of 87 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ALX
Oncology
Holdings Inc is $17.5​, above​ its last closing price of $7.70.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.88       -0.88      -0.84     Beat    4.5
 Mar. 31 2023  -0.82       -0.80      -0.74     Beat    7.7
 Dec. 31 2022  -0.81       -0.89      -0.75     Beat    15.4​
 Sep. 30 2022  -0.77       -0.77      -0.87     Missed  -12.9
 ​​Jun.        -0.64       -0.63      -0.81     Missed  -27.9
 30 2022                                                
 Mar. 31 2022  -0.71       -0.71      -0.60     Beat    15.8​
 Dec. 31 2021  -0.62       -0.62      -0.70     Missed  -13.1
 Sep. 30 2021  -0.47       -0.48      -0.61     Missed  -28.2
 This summary was machine generated November 3 at 12:53 GMT.  All
figures in US dollars  unless otherwise stated